Drug Trial Radar · NCT05394168
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
12
Actual
Start
Dec 9, 2022
Primary completion
Dec 4, 2024
Study completion Mar 4, 2025
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- May 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of HLX53 (an anti-TIGIT Fc fusion protein) in patients with advanced/metastatic solid tumors.
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
HLX53Biological
There are 5 preset dose groups, namely 30mg/QW, 150mg/QW, 400mg/QW, 1000mg/Q3W and 2000mg/Q3W, administered by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventTime frame: Through study completion, assessed up to 2 years.
- Incidence of DLTTime frame: Up to 3 weeks.
- MTDTime frame: Up to 3 weeks
- RP2DTime frame: Through study completion, assessed up to 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.